TOL-463 is an anti-infective medication which is under development for the treatment of bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) (vaginal yeast infection).

[1][2][4] EDTA enhances the antimicrobial activity of boric acid and improves its efficacy against relevant biofilms.

[1] In a small phase 2 randomized controlled trial, TOL-463 as an insert or gel achieved clinical cure rates of 50 to 59% against BV and 81 to 92% against VVC in women who had one or both conditions.

[4][2][1] It was effective and safe in the study, though it was without indication of superiority over other antifungal medications for VVC.

You can help Wikipedia by expanding it.This drug article relating to the genito-urinary system is a stub.